FDA Must Strive for Progress, Not Perfection


When it comes to research on promising new classes of pain therapies, the agency must weigh its understandable caution regarding safety concerns against unmet needs of millions of patients suffering with pain.

LOADING PDF: If there are any problems, click here to download the file.

Published In: Health Updates